Prostate cancer
mCRPC: novel and emerging agents

Willy (73 years old)

Willy, 73 years old, loves bird watching. He put several seed and nut feeders in his garden to attract  birds. He spends hours a day to identify the different species and to study their behaviour. He was diagnosed with PCa 7 years ago.

Medical history:

  • 7 years ago: RP for PCa (pT3bN0, ISUP grade 5, postoperative PSA <0.1 ng/ml)
  • 6 years ago: salvage RT for rising PSA (0.53 ng/ml)
  • 5 years ago: ADT started because of rising PSA (7 ng/ml), no metastases on conventional imaging
  • 2 years ago: progression to mCRPC (bone), 1st-line treatment with abiraterone, 2nd-line treatment with 6 cycles docetaxel

Current situation:

  • Rising PSA: from 0.9 ng/ml to 3.9 ng/ml
  • ECOG PS: 1
  • Back pain
  • MRI spine:
    • Progression of existing bone lesions and new bone lesions in multiple vertebrae
    • Enlarging soft tissue component at Th9 causing spinal cord compression
    • Neurosurgical decompression was performed
  • Histology from neurosurgical decompression: metastatic poorly-differentiated PCa
  • Somatic ATM mutation

Which of the following treatment options would you choose for this patient, following local management of the spinal cord compression?